Albireo Pharma Inc (ALBO)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in...

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company...

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study...

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company...

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes...

Albireo to Participate in Jefferies London Healthcare Conference

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company...

Albireo Reports Q3 2022 Financial Results and Business Update

Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease...

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-ter...

Albireo Announces 2022 SPARK Grant Winners

— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible...